This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

11 Biotech Stocks Loved or Hated by Hedge Funds

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Keryx Pharmaceuticals (KERX - Get Report)

Developer of the cancer drug perifosine, Keryx announced recently the completion of enrollment in a phase III colon cancer study, clearing the way for top-line results to be announced before the end of the year.

Year to date performance: -14%

Performance since June 30: -15%

Driehaus Capital Management and Highland Capital Management both opened new positions in Keryx during the quarter, while Balyasny Asset Management added to an existing position that totaled 3.3 million shares at the end of June.

Some small selling of Keryx occurred during the quarter from SAC Capital, Jefferies Group and Citadel Advisors.

5 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AMRN $2.37 1.28%
DSCI $8.23 -2.83%
IDIX $24.50 0.20%
KERX $12.37 -2.83%
ONTY $1.60 -1.84%


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs